Market Outlook

By 2035, the U.S. Rapid Point-of-Care Testing Devices Market is expected to reach approximately USD 15.43 billion, expanding at a CAGR of 9.20% during the forecast period 2026–2035. The market is estimated at USD 6.40 billion in 2025, with historical analysis covering 2021–2024. Values in this report are expressed in USD billions.

For the purpose of this report, rapid point-of-care testing devices include near-patient analyzers, portable diagnostic systems, reader-based platforms, single-use rapid diagnostic devices, instrument-specific cartridges and cassettes, and associated testing consumables designed to produce clinically actionable results during the same patient encounter. The market excludes conventional centralized laboratory platforms, continuous glucose monitoring systems, imaging-based diagnostics, and specimen-collection-only products.

The U.S. market is entering a structurally different growth phase from the COVID-19 emergency period. Pandemic-era testing established consumer familiarity with self-testing, accelerated CLIA-waived deployment, expanded retail and urgent-care testing infrastructure, and changed physician expectations around diagnostic turnaround time. The market is now transitioning from single-pathogen emergency testing toward sustainable platforms covering respiratory disease, diabetes, cardiometabolic testing, sexually transmitted infections, coagulation, pregnancy and fertility, hematology, and other near-patient applications.

The historical market is estimated to have expanded from approximately USD 4.72 billion in 2021 to USD 5.86 billion in 2024. Growth during this period was not uniform. COVID-19 antigen volumes normalized from exceptional pandemic levels, while demand strengthened for rapid molecular respiratory testing, glucose and HbA1c testing, cardiac-marker assessment, multiplex testing, and decentralized diagnostics in physician offices and urgent-care environments. By 2025, market value reached approximately USD 6.40 billion as manufacturers increasingly shifted their portfolios toward higher-value reader-based immunoassay systems, connected POC analyzers, and molecular platforms capable of producing PCR-quality results within the patient visit.

The forecast implies a market of approximately USD 6.99 billion in 2026, USD 9.94 billion in 2030, USD 10.85 billion in 2031, and USD 15.43 billion by 2035. Growth will increasingly be value-led rather than dependent solely on test volume. Multiplex respiratory testing, rapid molecular diagnostics, digitally connected testing, broader CLIA-waived menus, and decentralized chronic-disease testing will increase revenue per testing location while enabling more clinical decisions to be completed before patients leave the site of care.

Rapid POC testing is particularly well aligned with the structure of the U.S. healthcare delivery system. The country has approximately 6,100 hospitals, more than 907,000 staffed hospital beds, over 15,000 urgent-care centers, a broad physician-office network, thousands of community health sites, retail pharmacies with expanding clinical services, and approximately 320,000 laboratory entities operating under the CLIA regulatory framework. This infrastructure creates an unusually large addressable installed base for decentralized testing platforms.

The most important commercial transition through 2035 will be from “rapid result” as a differentiator to “rapid clinical resolution” as the purchasing objective. Health systems, urgent-care chains, physician groups, and pharmacies increasingly require technologies that reduce patient callbacks, limit send-out testing, accelerate therapeutic decisions, support antimicrobial stewardship, shorten emergency-department disposition time, and integrate results into electronic health records. Manufacturers able to deliver these workflow outcomes will command a stronger competitive position than suppliers competing primarily on analytical performance or test price.

 

Introduction

According to the U.S. Rapid Point-of-Care Testing Devices Market Report, rapid diagnostics have become a critical interface between laboratory medicine and frontline clinical decision-making. The value proposition is strongest when diagnostic information changes treatment during the encounter rather than several hours or days later. This makes rapid POC testing strategically important in emergency departments, urgent-care centers, physician practices, retail clinics, pharmacies, community health centers, hospital wards, ambulatory facilities, and selected home-testing applications.

Unlike conventional laboratory diagnostics, the economics of point-of-care testing cannot be evaluated only through reagent cost. The relevant economic comparison includes clinician time, patient throughput, send-out laboratory cost, follow-up communication, repeat visits, inappropriate treatment, isolation decisions, bed utilization, and the probability that a patient is lost to follow-up. A POC assay can therefore be economically attractive even when its per-test acquisition cost exceeds central-laboratory testing, provided it changes clinical management quickly enough to eliminate downstream utilization.

Respiratory disease is one of the clearest examples. Recent U.S. seasonal estimates have indicated tens of millions of influenza illnesses, millions of respiratory-related outpatient visits, and hundreds of thousands of influenza, COVID-19, and RSV hospitalizations within individual respiratory seasons. Influenza alone was associated with approximately 40 million illnesses and 18 million medical visits during the 2023–2024 season. During the subsequent respiratory season, COVID-19 and RSV continued to generate substantial outpatient and inpatient utilization. This recurrent disease burden supports a durable market for influenza, SARS-CoV-2, RSV, strep, and broader syndromic POC platforms.

Chronic disease is equally important. Approximately 38.4 million Americans have diabetes, while close to 98 million adults have prediabetes. This patient base sustains demand for glucose testing, HbA1c assessment, ketone testing, lipid profiling, and other rapid metabolic measurements. Unlike seasonal infectious-disease products, these categories generate recurring year-round utilization, providing manufacturers with more predictable demand and helping health systems justify decentralized analyzer placement.

The market also benefits from a large non-hospital care infrastructure. U.S. urgent-care centers now treat more than 185 million patients annually, while federally supported community health centers serve more than 32 million patients. These environments increasingly function as diagnostic decision nodes rather than simple referral points. A sore-throat patient can be tested for group A strep before an antibiotic decision; a respiratory patient can receive influenza, COVID-19, or RSV differentiation during the visit; a diabetic patient can receive an HbA1c result during routine management; and selected STI patients can increasingly receive actionable molecular results without waiting for a central laboratory.

Procurement behavior differs substantially by customer type. Large integrated delivery networks emphasize instrument standardization, connectivity, operator management, quality controls, enterprise contracting, and total cost per result. Urgent-care chains prioritize turnaround time, throughput, ease of training, minimal maintenance, small footprint, and predictable reagent economics. Independent physician offices require low capital commitment and simple CLIA-waived workflows. Retail pharmacies and consumer channels prioritize ease of use, distribution scalability, interpretation simplicity, and patient-facing usability.

The strategic opportunity through 2035 therefore lies not in treating rapid testing as a single device category but as a distributed diagnostic ecosystem. Winning platforms will connect test performance, workflow design, digital reporting, reimbursement, clinical decision support, and broad assay menus into a commercially coherent operating model.

 

Key Market Drivers: What’s Fueling the U.S. Rapid Point-of-Care Testing Devices Market Boom?

The first major driver is the structural decentralization of diagnostic testing. Approximately 320,000 U.S. laboratory entities are covered by CLIA, creating a broad regulatory and operational base for testing outside traditional reference and hospital laboratories. CLIA-waived devices are particularly important because they can be deployed in lower-complexity settings when used according to their authorized instructions. Every expansion of the waived test menu potentially increases the addressable customer base across physician offices, pharmacies, urgent-care centers, community clinics, and other decentralized environments.

A second driver is the persistent respiratory-infection burden. Influenza, COVID-19, RSV, and bacterial respiratory infections create a high-volume testing environment in which clinical symptoms overlap but treatment and infection-control decisions differ. Rapid differentiation therefore has value beyond simply confirming infection. The economics improve further when one cartridge or cassette can distinguish several pathogens. Multiplex respiratory testing is consequently moving from premium tertiary-care use toward community and outpatient care.

Group A streptococcal pharyngitis creates another recurring rapid-testing opportunity. Approximately 20%–30% of pharyngitis episodes in children and 5%–15% in adults are associated with group A strep. Because clinical examination alone cannot reliably distinguish bacterial from viral pharyngitis in patients without clear viral symptoms, rapid testing supports antibiotic stewardship and reduces unnecessary antimicrobial exposure. The commercial importance of this category is magnified by the high volume of pediatric, primary-care, retail-clinic, and urgent-care sore-throat visits.

A third driver is the scale of chronic metabolic disease. With more than 38 million people living with diabetes and a much larger population with prediabetes, rapid testing is embedded in routine disease management. Glucose remains one of the highest-volume POC analytes, while HbA1c testing is strategically attractive because results available during an office visit allow clinicians to modify treatment immediately rather than waiting for a laboratory result and initiating a second patient interaction.

A fourth driver is the expansion of urgent care, community health, retail medicine, and outpatient clinical delivery. More than 15,000 U.S. urgent-care centers now operate nationally, compared with roughly 9,000 in 2016. These facilities collectively treat over 185 million patients each year. Rapid testing is central to the urgent-care business model because the setting competes on access and same-visit resolution. Waiting one or two days for a laboratory result undermines the economic proposition of the care model.

Community health centers represent another substantial opportunity. More than 32 million patients received care through federally supported health centers in 2024. These sites are disproportionately important in rural, low-income, medically underserved, and high-chronic-disease populations. Compact POC platforms can reduce transportation barriers, loss to follow-up, and dependence on external laboratories, particularly for diabetes, infectious disease, pregnancy, HIV, hepatitis, and selected STI testing.

A fifth driver is hospital workflow economics. U.S. hospitals report more than 35 million admissions annually. Rapid testing can influence emergency-department triage, antimicrobial initiation, respiratory isolation, anticoagulation management, glycemic control, cardiac evaluation, and discharge decisions. Procurement committees increasingly ask whether a POC device reduces time-to-treatment, patient length of stay, laboratory workload, unnecessary isolation, or repeat clinical encounters. A technology that saves meaningful clinician or bed time can justify premium reagent costs.

A sixth driver is rising consumer acceptance of self-testing. The pandemic normalized at-home specimen collection, lateral-flow interpretation, digital test instructions, telehealth-linked diagnostics, and OTC diagnostic purchasing. The market is now extending this behavior into combination influenza/COVID-19 testing, HIV testing, pregnancy and fertility, and potentially additional infectious-disease applications. The long-term commercial question is not whether consumers will test at home, but which tests have sufficient clinical utility, affordability, reliability, and follow-up pathways to sustain routine demand.

A seventh driver is regulatory migration from emergency authorization toward traditional marketing pathways. The rapid-testing industry is moving into a more mature post-pandemic phase in which manufacturers must build durable portfolios under conventional FDA pathways. Traditional clearances for respiratory combination tests, CLIA-waived molecular systems, and OTC products support greater purchasing confidence among hospitals, physician practices, retailers, and distributors because product availability is no longer dependent on temporary emergency frameworks.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in rapid POC testing is increasingly centered on time-to-action rather than analytical turnaround time alone. A test that produces a result in ten minutes but requires complicated sample preparation or manual interpretation may create less operational value than a fifteen-minute cartridge with automated processing, digital interpretation, connectivity, and minimal hands-on time.

Ultra-fast molecular testing is one of the most important innovation cycles. Traditional molecular diagnostics historically required laboratory infrastructure and longer turnaround times. New compact PCR and nucleic-acid amplification platforms are reducing result times toward ten to twenty minutes, with some newer systems designed to return selected results in approximately six to ten minutes. This materially changes where molecular testing can be economically deployed.

The clinical implication is important. Antigen testing has historically dominated many high-volume rapid applications because it is inexpensive and operationally simple. Molecular platforms offer higher analytical sensitivity but traditionally carried higher instrument and reagent costs. As molecular testing becomes faster, smaller, easier to operate, and CLIA waived, the competitive boundary between antigen and molecular testing shifts. Urgent-care chains and physician offices can increasingly evaluate molecular platforms based on the value of higher diagnostic confidence rather than dismissing them as laboratory-only technologies.

Multiplexing represents a second innovation frontier. Respiratory symptoms frequently cannot differentiate influenza, COVID-19, RSV, rhinovirus, human metapneumovirus, pertussis, or bacterial throat infection. Syndromic platforms capable of identifying multiple viral and bacterial targets from one specimen can reduce sequential testing and improve therapeutic selection. Platforms offering both limited and broad panels are particularly attractive because they allow clinicians to match test cost with clinical complexity.

The market is also advancing through digital immunoassay readers. Instrument interpretation can reduce subjective visual reading, standardize workflow, support automatic result documentation, enable quality-control tracking, and connect results to laboratory information systems or electronic records. This is particularly relevant to multi-site urgent-care chains and integrated delivery networks, where inconsistent manual documentation creates operational and compliance risk.

Microfluidics and cartridge engineering are reducing sample-handling requirements. The strongest POC designs increasingly combine specimen preparation, reagent storage, amplification or reaction chemistry, detection, interpretation, and disposal within a single cartridge. Lower hands-on time allows testing to be performed by medical assistants, nurses, pharmacists, and other trained personnel without creating laboratory-style workflow complexity.

Connectivity is becoming a procurement requirement rather than an optional feature. Health systems increasingly expect POC devices to support patient identification, operator lockout, quality-control logs, result transmission, middleware integration, remote device management, and cybersecurity standards. A device that generates clinically accurate results but requires manual transcription into the EHR can create significant hidden labor and error risk across hundreds of testing locations.

Home-testing innovation is moving toward multiplex and digitally supported models. The authorization of combination influenza and COVID-19 OTC testing represented an important commercial milestone because it showed that multi-pathogen differentiation could move into the consumer environment. Future growth will depend on linking home results with appropriate medical action, including antiviral eligibility, telehealth consultation, confirmatory testing, and public-health reporting where required.

Manufacturers are also investing in menu breadth. Instrument placement economics improve when one analyzer can support respiratory testing in winter, strep testing throughout the year, sexually transmitted infections, coagulation, HbA1c, cardiac biomarkers, or other assays. Broader menus increase utilization per instrument and reduce the risk that a platform becomes economically dependent on one seasonal indication.

 

Segmentation Insights

The U.S. Rapid Point-of-Care Testing Devices Market is segmented on the basis of product category, application, end user, technology type, and region.

 

By Product Category

Rapid Infectious Disease Testing Devices

Rapid infectious disease testing represents the largest and most strategically dynamic product category. The segment includes influenza, COVID-19, RSV, strep A, HIV, hepatitis, sexually transmitted infection, gastrointestinal, and other pathogen-focused systems. Respiratory testing remains the largest near-term opportunity because seasonal disease volumes are high and symptoms overlap. Increasing availability of combination antigen tests and multiplex molecular systems is shifting revenue from single-pathogen products toward higher-value multi-analyte formats.

The segment is also moving beyond respiratory disease. HIV rapid tests can provide results in approximately thirty minutes or less, while selected point-of-care molecular technologies are extending into sexual-health applications. The commercial advantage is strongest where immediate diagnosis influences treatment, partner management, counseling, or the likelihood that a patient returns for results.

Blood Glucose and Diabetes POC Devices

Blood glucose and diabetes-related devices provide the market with a stable recurring revenue base. Hospital glucose meters, physician-office analyzers, HbA1c systems, ketone devices, and associated strips and cartridges support millions of patients requiring ongoing metabolic monitoring.

The category is mature in conventional glucose measurement, but differentiation continues through interference resistance, connectivity, operator controls, improved sample handling, and hospital information-system integration. HbA1c represents a more attractive growth subsegment because same-visit testing enables immediate medication adjustment and supports chronic-disease quality programs. Rapid lipid and metabolic testing can further expand the economic role of primary-care POC platforms.

Cardiometabolic and Cardiac Marker POC Systems

Cardiac and cardiometabolic devices include troponin, BNP or NT-proBNP, lipid, and related acute-care testing technologies. Their primary value is accelerated clinical decision-making in emergency and acute-care workflows. High-sensitivity cardiac testing remains more technically demanding than simple lateral-flow applications, but the strategic demand is strong because chest-pain evaluation consumes significant emergency-department capacity.

POC cardiac testing is most commercially attractive when results can be aligned with validated clinical pathways and central-laboratory standards. Hospitals will evaluate these systems on assay quality, turnaround time, connectivity, quality controls, and whether testing materially shortens clinical disposition.

Coagulation and Hemostasis POC Devices

Coagulation testing includes PT/INR devices, activated clotting time systems, and other rapid hemostasis technologies used in anticoagulation clinics, operating environments, cardiac procedures, emergency care, and selected home-monitoring applications. The segment benefits from recurring testing among patients receiving anticoagulant therapy and from the need for immediate coagulation information during invasive procedures.

Competition increasingly focuses on precision, low sample volume, connectivity, cartridge stability, and operator simplicity. Point-of-care coagulation remains particularly valuable where a delay of even thirty to sixty minutes can interrupt procedure flow or postpone medication decisions.

Pregnancy, Fertility and Women’s Health Rapid Tests

Pregnancy testing is one of the most established rapid-testing categories and remains a high-volume market across hospitals, physician offices, retail settings, and home use. Growth is increasingly shifting toward digitally interpreted fertility products, connected ovulation testing, and point-of-care women’s health diagnostics rather than basic pregnancy strips alone.

Future opportunity is expected to broaden as molecular and microfluidic platforms address vaginitis and sexually transmitted infections closer to the patient. These conditions are particularly compatible with POC testing because overlapping symptoms can lead to empiric treatment when rapid etiologic information is unavailable.

Other Rapid POC Testing Devices

The remaining category includes rapid hematology, blood gas and electrolyte testing, urinalysis, renal-function markers, fecal occult blood testing, cholesterol systems, and other near-patient diagnostic products. Many of these categories are highly embedded in specific workflows rather than broadly distributed across all care settings.

Blood gas and electrolyte systems remain important in emergency, operating-room, neonatal, and critical-care environments, while compact urinalysis platforms are increasingly relevant in physician offices and outpatient facilities. The commercial opportunity is driven by analyzer consolidation and the ability to move multiple routine diagnostic decisions closer to the patient.

 

By Application

Respiratory Infection Diagnosis

Respiratory testing is the most important near-term growth application. Influenza, COVID-19, RSV, strep-associated illness, and other respiratory conditions create substantial winter demand and increasingly year-round testing needs. Recent seasons have continued to generate millions of outpatient visits and hundreds of thousands of hospitalizations associated with major respiratory viruses.

The competitive trend is moving toward combination tests and syndromic panels. A single respiratory encounter may now support testing for three, five, or more targets depending on the clinical setting. Hospitals tend to favor more comprehensive molecular testing for complex patients, while urgent-care and physician-office environments balance menu breadth against cost per encounter.

Diabetes and Metabolic Disease Management

Diabetes management generates stable testing volume independent of seasonal infectious-disease cycles. With more than 38 million Americans living with diabetes, glucose and HbA1c measurements remain core POC applications.

Same-visit HbA1c is especially relevant to primary care, endocrinology, community health, and population-health programs. The result can be discussed directly with the patient, reducing the operational friction associated with off-site laboratory testing and follow-up communication. Future growth will increasingly involve integrated metabolic panels and digitally connected chronic-disease workflows rather than isolated glucose measurement.

Acute Cardiac and Critical-Care Decision Support

Rapid cardiac biomarkers, blood gas, electrolytes, lactate, coagulation, and related assays support emergency, intensive-care, and procedural workflows. In these applications, minutes can influence treatment and disposition.

The economic case is therefore closely tied to workflow. Hospitals may accept higher per-test costs when near-patient testing reduces central-laboratory transport delays, accelerates a clinical pathway, improves operating-room throughput, or enables earlier discharge. Manufacturers must demonstrate not only analytical performance but also measurable operational benefit.

Infectious Disease and Sexual-Health Screening

Beyond respiratory disease, rapid testing has expanding relevance in HIV, hepatitis, sexually transmitted infections, and selected community-health programs. HIV rapid testing can produce results during the same encounter, reducing loss to follow-up and enabling immediate counseling.

Molecular POC testing could transform STI management because patients are frequently treated empirically or asked to wait for laboratory results. Platforms capable of delivering pathogen-specific results within the visit could support targeted treatment and antimicrobial stewardship, although reimbursement, test cost, and workflow integration will determine the pace of adoption.

Pregnancy, Fertility and Women’s Health

Pregnancy testing remains routinely embedded across emergency departments, physician offices, obstetric and gynecologic practices, pharmacies, and home settings. Testing often influences medication, imaging, and procedural decisions immediately, making rapid results operationally essential.

Growth within women’s health is likely to come from expanded POC diagnostic menus addressing vaginal infections, reproductive-health conditions, and sexually transmitted infections. These applications have strong potential because same-visit etiologic diagnosis can materially improve treatment selection.

Coagulation and Anticoagulation Management

Coagulation POC testing supports anticoagulation clinics, surgical services, cardiac catheterization, emergency departments, and selected patient self-testing. The application is characterized by repeated testing and high clinical sensitivity to inaccurate results.

Healthcare providers therefore place significant emphasis on quality control, device reliability, operator competency, and data capture. Growth is likely to remain steady rather than explosive, but the segment provides durable recurring revenue and high customer retention once a platform is embedded into clinical workflow.

 

By End User

Hospitals and Health Systems

Hospitals remain the largest institutional end-user group because they combine high patient volumes with multiple POC applications. U.S. hospitals operate more than 907,000 staffed beds and record over 35 million admissions annually, creating large testing volumes across emergency departments, inpatient units, intensive care, operating rooms, neonatal care, and ambulatory hospital departments.

Large health systems increasingly standardize POC platforms across multiple facilities. Procurement decisions therefore consider analyzer fleet management, reagent contracts, service response, interface capability, quality assurance, staff training, cybersecurity, and enterprise pricing. Vendors able to support integrated POC management across hundreds of devices have an advantage over smaller suppliers offering isolated instruments.

Physician Offices and Primary-Care Clinics

Physician offices represent one of the most important decentralized growth opportunities. Primary-care physicians, pediatricians, family medicine practices, endocrinologists, obstetric and gynecologic clinics, and specialty offices increasingly use rapid diagnostics to complete treatment decisions during the visit.

The ideal device for this segment requires minimal maintenance, simple sample preparation, CLIA-waived operation where feasible, compact footprint, predictable per-test economics, and rapid results. Broad test menus can improve instrument utilization because physician offices typically cannot justify dedicated analyzers for low-volume applications.

Urgent-Care and Retail Clinics

Urgent care is among the highest-growth end-use environments. The United States has more than 15,000 urgent-care centers treating over 185 million patients annually. Respiratory disease, sore throat, urinary symptoms, minor acute illness, and occupational health generate substantial demand for immediate diagnostics.

The economics favor rapid tests because the urgent-care model depends on resolving the patient encounter quickly. Platforms that require extensive hands-on time or create bottlenecks are less attractive even if their analytical performance is strong. Large urgent-care operators also value centralized connectivity, standardized protocols, inventory visibility, and national distribution support.

Retail clinics and pharmacy-based testing are likely to increase their role as states expand pharmacist scope and consumers seek convenient healthcare access. Manufacturers that design testing systems around retail workflow rather than traditional laboratory workflow could benefit disproportionately.

Home Care and Self-Testing

Home and self-testing represent a structurally important long-term segment. The COVID-19 pandemic created unprecedented consumer familiarity with rapid diagnostic testing, and subsequent regulatory activity has expanded the availability of combination respiratory products.

Home testing competes on different criteria from professional POC systems. Price, shelf stability, packaging, ease of specimen collection, clarity of interpretation, and access to follow-up care are critical. Digital connectivity could become more important where results need to be linked to telehealth treatment or antiviral prescribing.

Community Health Centers, Pharmacies and Other Decentralized Sites

Community health centers are strategically significant because they serve more than 32 million patients and frequently manage populations with elevated chronic disease burden and barriers to laboratory access. Rapid testing can reduce loss to follow-up and improve same-day clinical decision-making.

Pharmacies, correctional facilities, employer clinics, mobile-health units, school health programs, nursing facilities, and public-health outreach sites add another layer of distributed demand. These settings favor simple, rugged, CLIA-waived systems and can become particularly important for screening, outbreak response, respiratory testing, HIV testing, and chronic-disease assessment.

 

By Technology Type

Lateral Flow Immunoassay

Lateral flow remains the highest-volume rapid-testing technology because it is inexpensive, portable, scalable, and familiar to both clinicians and consumers. It is heavily used in respiratory antigen testing, pregnancy testing, infectious-disease screening, and other single-use applications.

The technology is evolving from single-target visual interpretation toward combination tests, improved signal chemistry, reader-assisted interpretation, and digitally connected workflows. Its principal competitive advantage remains cost and simplicity, although sensitivity limitations can favor molecular testing in applications where diagnostic certainty has greater clinical value.

Molecular PCR and Nucleic Acid Amplification

Rapid molecular testing is expected to be the fastest-growing technology segment through 2035. Compact PCR and other nucleic-acid amplification systems are increasingly capable of delivering highly sensitive results within approximately ten to thirty minutes.

CLIA-waived molecular platforms expand the technology into urgent care and physician offices. The major commercial constraint remains per-test cost, but this can be offset when the result reduces repeat visits, inappropriate antibiotic use, confirmatory testing, or delayed therapy. Ultra-fast PCR systems are likely to intensify competition with premium digital immunoassays.

Electrochemical and Biosensor-Based Testing

Electrochemical biosensors form the technological backbone of glucose testing and are used across additional blood-based applications. Their strengths include rapid measurement, low sample volume, mature manufacturing economics, and compatibility with portable devices.

Innovation is focused on interference reduction, connectivity, calibration control, multiplex sensing, and integration into broader POC platforms. Because glucose testing is already highly penetrated, future growth will depend more on replacement cycles, hospital connectivity upgrades, and expansion into adjacent analytes.

Fluorescence and Digital Immunoassay

Fluorescence immunoassay and digitally interpreted antigen systems occupy an intermediate position between visual lateral-flow testing and molecular diagnostics. Reader-based interpretation can improve standardization, reduce subjective errors, enable semi-quantitative results, and automate documentation.

These systems remain attractive to urgent-care chains, physician offices, and hospitals seeking higher workflow control without the cost structure of molecular testing. Their strategic challenge is that increasingly fast PCR platforms are narrowing the turnaround-time advantage.

Microfluidic and Cartridge-Based Integrated Systems

Microfluidic systems are becoming an important cross-platform technology because they can automate multiple testing steps within a disposable cartridge. Sample preparation, reagent handling, reaction chemistry, detection, and waste containment can be integrated with minimal operator interaction.

The technology is particularly important for molecular diagnostics, compact chemistry, and emerging multiplex assays. Through 2035, successful platforms will be those that combine low hands-on time with broad menus and strong manufacturing economics. The cartridge is increasingly becoming the core commercial asset because recurring consumables generate the majority of lifetime platform revenue.

 

Regional Insights: Where the Market is Growing Fastest

The U.S. Rapid Point-of-Care Testing Devices Market is geographically segmented into the South, West, Northeast, and Midwest. Regional performance differs according to population, age structure, chronic-disease burden, respiratory-disease utilization, hospital and urgent-care density, outpatient migration, rural access, academic medical center concentration, retail-health adoption, and payer mix.

The South represents the largest regional market in 2025, while the West is projected to record the fastest CAGR through 2035. The Northeast maintains a high-value market characterized by sophisticated health systems and rapid adoption of advanced molecular platforms. The Midwest provides a large, stable base of hospital, community, rural, and chronic-disease testing demand.

South

The South represents an estimated USD 2.30 billion market in 2025 and is projected to reach approximately USD 5.60 billion by 2035, reflecting an estimated regional CAGR of about 9.31%.

For this report, the region includes Texas, Florida, Georgia, North Carolina, South Carolina, Virginia, West Virginia, Maryland, Delaware, Kentucky, Tennessee, Alabama, Mississippi, Arkansas, Louisiana, Oklahoma, and the District of Columbia.

The region benefits from the largest aggregate population base among U.S. census regions, high diabetes and cardiometabolic disease burden in multiple states, rapid metropolitan growth, strong urgent-care expansion, and significant rural healthcare needs. These characteristics create demand at both ends of the POC spectrum: high-value molecular platforms in major metropolitan health systems and simplified waived testing technologies in smaller community settings.

Texas is expected to remain one of the two largest state opportunities nationally. Houston, Dallas-Fort Worth, Austin, and San Antonio support extensive hospital and urgent-care networks, while rural West and South Texas create a separate requirement for decentralized testing where central-laboratory access may involve longer transportation time. Texas is particularly attractive for respiratory POC, glucose and HbA1c testing, emergency diagnostics, and community-based testing.

Florida is another major demand center because of its large population, substantial older-adult cohort, dense healthcare infrastructure, and extensive urgent-care and retail-clinic footprint. Respiratory testing is commercially important because older adults experience greater risk from influenza, COVID-19, and RSV. Diabetes and cardiometabolic testing also provide strong recurring demand.

North Carolina, Georgia, Tennessee, and Virginia are high-growth markets supported by population expansion, health-system investment, research institutions, and growing outpatient infrastructure. Major academic and integrated health systems in these states often serve as early adopters of molecular POC platforms before broader penetration into community practice.

Maryland and the District of Columbia benefit from dense healthcare and research infrastructure. Delaware is smaller by population but highly accessible to regional laboratory and health-system networks. South Carolina continues to attract provider investment as population growth increases demand for outpatient services.

Alabama, Mississippi, Louisiana, Arkansas, Kentucky, Oklahoma, and West Virginia present a different commercial profile. High chronic-disease burden and substantial rural populations increase the need for rapid diabetes, respiratory, coagulation, and basic metabolic testing, but hospital consolidation, clinician shortages, and purchasing constraints can limit adoption of premium capital-intensive systems. Low-footprint CLIA-waived devices with predictable reagent cost are particularly well suited to these markets.

The South should retain the largest national share through 2035. Manufacturers that combine enterprise contracting for large metropolitan systems with scalable solutions for community, retail, and rural settings will be best positioned.

West

The West represents an estimated USD 1.47 billion in 2025 and is expected to reach approximately USD 3.78 billion by 2035, representing the fastest regional CAGR at approximately 9.90%.

The region includes California, Washington, Oregon, Arizona, Nevada, Colorado, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska, and Hawaii.

California is the dominant Western state and one of the most strategically important markets nationally. Its scale, large integrated health systems, academic medical centers, biotechnology ecosystem, diagnostic companies, digital-health adoption, and large urgent-care population make it a critical launch market. California providers are especially receptive to connected POC platforms, multiplex respiratory testing, decentralized molecular diagnostics, and digitally supported consumer testing.

Large California health systems increasingly evaluate POC products at enterprise scale. Connectivity, cybersecurity, EHR integration, quality management, and standardized device fleets can therefore matter as much as assay performance. The state is also important for OTC and retail-testing innovation because of its large consumer market.

Arizona and Nevada offer above-average growth because of population migration, aging demographics, and expanding healthcare systems. Respiratory testing, metabolic disease management, and urgent-care diagnostics are particularly attractive in major population centers.

Washington and Oregon benefit from sophisticated integrated delivery networks and strong digital-health adoption. These states are likely to be early markets for connected analyzers, data-integrated POC management, and platforms that align decentralized testing with enterprise laboratory governance.

Colorado and Utah combine population growth with strong healthcare systems and innovation-oriented provider networks. Both markets are well suited to outpatient molecular diagnostics and multi-site physician-group deployment.

New Mexico, Idaho, Montana, Wyoming, Alaska, and Hawaii are smaller markets but strategically important for decentralized diagnostics because geographic distance can increase the operational cost of centralized laboratory testing. Portable platforms with limited sample preparation can provide disproportionate value where transportation delays would otherwise prevent same-visit treatment.

The West is forecast to gain national share through 2035 as rapid testing becomes more digitally connected, molecular, consumer-accessible, and outpatient-oriented.

Northeast

The Northeast represents an estimated USD 1.41 billion market in 2025 and is forecast to reach approximately USD 3.34 billion by 2035, implying a regional CAGR of approximately 9.01%.

The region includes New York, Pennsylvania, New Jersey, Massachusetts, Connecticut, Rhode Island, Maine, New Hampshire, and Vermont.

The Northeast has one of the country’s highest concentrations of academic medical centers, diagnostic laboratories, specialist networks, and sophisticated integrated delivery systems. The region therefore tends to adopt advanced technologies earlier but subject them to rigorous value analysis.

New York is the largest Northeastern state market. New York City and other major metropolitan regions support substantial emergency, urgent-care, ambulatory, and physician-office testing volumes. Multi-site health systems represent attractive enterprise accounts, while dense urban urgent-care networks generate recurring respiratory and infectious-disease testing demand.

Pennsylvania and New Jersey provide large, diversified customer bases spanning academic hospitals, community systems, physician groups, retail health, and suburban urgent care. Both states are attractive for respiratory, diabetes, cardiac, and molecular POC testing.

Massachusetts has disproportionate strategic importance relative to population because of its academic hospitals, biotechnology ecosystem, diagnostic innovation, and early-stage technology companies. Novel POC molecular and microfluidic systems frequently obtain influential clinical evaluation within the state’s research-oriented provider network.

Connecticut and Rhode Island benefit from dense provider networks and proximity to major Northeast referral centers. Maine, New Hampshire, and Vermont have smaller populations but meaningful rural geographies in which decentralized testing can reduce transportation and laboratory turnaround barriers.

Growth in the Northeast will be slightly below the West because many major health systems already have advanced POC capabilities. Revenue expansion will therefore rely more heavily on premium replacement cycles, broader molecular menus, analyzer consolidation, and outpatient deployment than first-time adoption.

Midwest

The Midwest accounts for an estimated USD 1.22 billion in 2025 and is expected to reach approximately USD 2.71 billion by 2035, producing an estimated CAGR of around 8.31%.

The region includes Illinois, Ohio, Michigan, Indiana, Wisconsin, Minnesota, Missouri, Iowa, Kansas, Nebraska, North Dakota, and South Dakota.

The Midwest combines large metropolitan health systems with broad rural geographies and high chronic-disease prevalence in several states. This creates a stable market for glucose, HbA1c, coagulation, respiratory testing, cardiac markers, blood gas, and other near-patient testing products.

Illinois leads regional demand because of the Chicago healthcare market and large network of academic, community, ambulatory, and urgent-care facilities. Ohio is another major state opportunity with strong hospital systems and high diagnostic utilization across Cleveland, Columbus, Cincinnati, and other metropolitan areas.

Michigan provides substantial respiratory, diabetes, emergency, and cardiometabolic testing demand. Minnesota is strategically important because of its medtech ecosystem, integrated healthcare organizations, and strong culture of clinical technology adoption.

Indiana, Wisconsin, and Missouri provide meaningful hospital and physician-office markets with growing outpatient infrastructure. Iowa and Kansas combine regional referral centers with large rural catchment areas, strengthening the case for decentralized testing.

Nebraska, North Dakota, and South Dakota are smaller in absolute revenue but provide a strong use case for portable diagnostics because care is distributed across long distances. Connectivity and remote quality management are particularly important in these states because one laboratory program may oversee devices across multiple rural hospitals or clinics.

The Midwest is unlikely to grow as quickly as the West or South, but its installed healthcare base, chronic-disease burden, and rural diagnostic requirements create durable recurring demand.

 

Key Market Players

The U.S. Rapid Point-of-Care Testing Devices competitive landscape is moderately consolidated in major platform categories but remains fragmented across individual analytes and technologies.

Large diagnostic companies benefit from installed analyzer bases, national distribution, hospital contracting, regulatory expertise, manufacturing scale, and broad test menus. Smaller companies can still gain share where they offer a materially faster workflow, lower-cost cartridge, new CLIA-waived application, better home-testing experience, or an assay unavailable on incumbent platforms.

Some of the key players operating in the U.S. Rapid Point-of-Care Testing Devices industry include Abbott Laboratories, Roche Diagnostics, QuidelOrtho Corporation, Becton, Dickinson and Company, Cepheid, bioMérieux, Siemens Healthineers, Werfen, Nova Biomedical, Radiometer Medical, DiaSorin, QIAGEN, OraSure Technologies, Trinity Biotech, SEKISUI Diagnostics, ACON Laboratories, Access Bio, iHealth Labs, Healgen Scientific, Wondfo, ARKRAY, EKF Diagnostics, PTS Diagnostics, Visby Medical, and Baebies.

Abbott has one of the strongest competitive positions because it participates across rapid antigen testing, molecular testing, glucose monitoring, HbA1c, cardiometabolic testing, and other decentralized diagnostic categories. Its broad commercial footprint gives it access to hospitals, physician offices, urgent care, retail, and consumer channels.

Roche has strengthened its decentralized strategy through its cobas liat molecular platform and the acquisition of LumiraDx’s point-of-care technology. The strategic logic is important: a broad POC platform spanning immunochemistry, clinical chemistry, coagulation, and molecular testing could improve account penetration while increasing menu utilization.

QuidelOrtho remains a major rapid-testing competitor through Sofia, QuickVue, and associated immunoassay technologies and is expanding its molecular strategy. Its acquisition of LEX Diagnostics in 2026 adds an ultra-fast PCR platform designed to produce respiratory results in approximately six to ten minutes, positioning the company to compete more directly with Abbott, Roche, Cepheid, and other molecular POC suppliers.

BD has a strong position in digital antigen testing and hospital diagnostics. Cepheid remains one of the most recognized molecular diagnostic companies through the GeneXpert ecosystem, while bioMérieux has moved syndromic PCR closer to the patient through its SPOTFIRE platform.

Competition through 2035 will increasingly involve platform economics rather than individual test performance. Companies will compete on number of available assays, percentage of tests receiving CLIA waiver, turnaround time, sample preparation, instrument uptime, connectivity, reagent pricing, service infrastructure, and ability to generate sufficient test volume per instrument.

Hospital contracting will remain difficult for emerging entrants because health systems increasingly seek fewer device platforms and stronger enterprise standardization. Startups must therefore show a sufficiently differentiated clinical or economic advantage to justify introducing another analyzer into the hospital device fleet.

Urgent care and physician offices offer a different competitive route. A faster, simpler platform can gain traction quickly if it improves patient throughput and requires minimal operator training. This makes the outpatient market particularly attractive for ultra-fast molecular diagnostics.

 

Recent Developments

Recent U.S. market developments demonstrate that rapid testing is shifting from pandemic-driven antigen products toward a broader, more durable decentralized diagnostics ecosystem.

In March 2024, the BIOFIRE SPOTFIRE Respiratory/Sore Throat Panel received U.S. clearance and CLIA-waived status. The platform can detect multiple viral and bacterial respiratory or sore-throat targets in approximately fifteen minutes, illustrating how syndromic molecular testing is moving from central laboratories into physician-office and urgent-care workflows.

In July 2024, Roche completed the acquisition of LumiraDx’s point-of-care technology. The transaction strengthened Roche’s ability to build a broader decentralized testing portfolio across clinical chemistry, immunochemistry, coagulation, and molecular diagnostics. From a competitive perspective, the acquisition highlights the strategic value placed on multi-assay POC platforms rather than single-test technologies.

In October 2024, the first OTC home influenza and COVID-19 combination antigen test to receive U.S. marketing authorization through a traditional premarket pathway became available. The test provides results in approximately fifteen minutes and represented an important transition from emergency-authorized home testing to a durable post-emergency regulatory model.

During 2025, the U.S. regulatory environment broadened further. Additional combination COVID-19/influenza antigen tests gained traditional authorization, while respiratory molecular systems covering influenza, SARS-CoV-2, and RSV expanded their conventional commercial pathways. This increasing density of authorized products is intensifying competition and reducing the ability of manufacturers to rely on a single respiratory test.

Roche’s cobas liat respiratory molecular menu advanced in April 2025 with traditional U.S. authorizations for rapid SARS-CoV-2/influenza and SARS-CoV-2/influenza/RSV testing. The significance extends beyond one product. It demonstrates continued movement toward compact molecular systems capable of delivering high-value respiratory differentiation at decentralized sites.

In 2025, traditional marketing authorizations also expanded across visual lateral-flow and instrument-read antigen technologies, including products from Abbott, BD, Access Bio, ACON, Wondfo, and other suppliers. Respiratory rapid testing is therefore moving toward a crowded multi-vendor environment in which price, retail distribution, test menu, and supply-chain execution will become increasingly important.

In February 2026, the LEX VELO molecular respiratory platform received U.S. clearance and CLIA-waived status. The system was designed to provide influenza A, influenza B, and COVID-19 PCR results in approximately six to ten minutes. In April 2026, QuidelOrtho completed its acquisition of LEX Diagnostics for approximately USD 100 million, strengthening its position in ultra-fast molecular point-of-care testing.

Also during 2026, additional rapid respiratory molecular systems gained U.S. marketing authorization, reinforcing the transition toward faster PCR technologies that can operate in waived environments. The effect is likely to be greater competition between premium antigen and molecular testing rather than simply between competing molecular suppliers.

The broader strategic trend is clear. Manufacturer investment is concentrating around three themes: moving laboratory-grade analytical technologies into lower-complexity settings, expanding test menus on existing POC platforms, and reducing total time between specimen collection and therapeutic decision.

 

Conclusion

The U.S. Rapid Point-of-Care Testing Devices Market Size & Share is positioned for strong expansion from approximately USD 6.40 billion in 2025 to USD 15.43 billion by 2035, representing a 9.20% CAGR during 2026–2035.

The market’s long-term growth is supported by the intersection of disease burden and healthcare-delivery economics. More than 38 million Americans live with diabetes, seasonal respiratory diseases continue to generate tens of millions of illnesses and substantial hospitalization burden, U.S. hospitals record more than 35 million annual admissions, urgent-care centers treat more than 185 million patients each year, community health centers serve more than 32 million patients, and the CLIA framework encompasses approximately 320,000 laboratory entities.

These numbers create a large testing opportunity, but they do not guarantee success for every manufacturer. The decisive competitive issue is whether a platform can convert diagnostic speed into measurable clinical and operational value.

Rapid molecular testing is likely to capture a disproportionate share of value growth because newer systems are narrowing the historical turnaround-time gap between PCR and antigen testing. Multiplex respiratory platforms will continue to gain adoption because one test can replace sequential pathogen testing and improve therapeutic decisions. Digital immunoassay and lateral-flow systems will remain highly relevant because of their lower cost and operational simplicity.

The hospital market will increasingly reward integrated platforms with strong connectivity, enterprise quality management, and broad assay menus. Urgent-care and physician-office customers will prioritize low hands-on time, fast turnaround, CLIA-waived operation, and predictable per-patient economics. Consumer testing will expand where products offer clinically meaningful results and straightforward follow-up pathways.

Regional opportunity will remain strongest in the South, which is estimated at USD 2.30 billion in 2025 and could approach USD 5.60 billion by 2035. The West is expected to achieve the fastest growth, increasing from approximately USD 1.47 billion to USD 3.78 billion. The Northeast will remain a high-value market for advanced molecular and integrated testing, while the Midwest will provide stable demand across hospital, chronic-disease, community, and rural applications.

Texas, Florida, California, New York, Pennsylvania, Illinois, Ohio, Georgia, North Carolina, Massachusetts, Arizona, Washington, Michigan, and New Jersey will remain especially important commercial states because of their population scale, hospital infrastructure, urgent-care density, chronic-disease burden, and advanced provider networks. Smaller and rural states will remain commercially relevant where decentralized diagnostics can materially reduce specimen transport and patient follow-up barriers.

For clients evaluating this market, the critical strategic question is no longer whether healthcare testing will become more decentralized. That transition is already established. The more valuable questions are which assays can economically migrate away from central laboratories, which platforms can generate sufficient utilization per installed analyzer, how rapidly molecular testing can reach antigen-like workflow economics, and which manufacturers can secure durable enterprise and outpatient installed bases.

Companies able to combine analytical reliability, short turnaround time, broad CLIA-waived menus, digital connectivity, supply-chain consistency, reimbursement support, and demonstrable workflow savings will be best positioned to capture the next decade of value creation in the U.S. Rapid Point-of-Care Testing Devices Market.

 

TABLE OF CONTENT

1. U.S. Rapid Point-of-Care Testing Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Market Sizing, Triangulation & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Rapid Point-of-Care Testing Device Manufacturers
1.6.2. Assay, Reagent, Biosensor & Cartridge Suppliers
1.6.3. Contract Manufacturing and Diagnostic Component Suppliers
1.6.4. Hospitals and Integrated Delivery Networks
1.6.5. Physician Offices, Urgent-Care Centers and Retail Clinics
1.6.6. Community Health Centers and Decentralized Testing Sites
1.6.7. Pharmacies and Home/Self-Testing Channels
1.6.8. Clinical Laboratories and Point-of-Care Coordinators
1.6.9. Group Purchasing Organizations and Diagnostic Distributors
1.6.10. CMS, FDA, CDC, Payers and Other Regulatory Stakeholders

What this section provides: This section establishes the definition and boundaries of the U.S. Rapid Point-of-Care Testing Devices Market, explains the research and forecasting methodology, and identifies the stakeholders influencing device adoption, assay utilization, regulatory access, reimbursement, distribution, and decentralized testing demand.

2. U.S. Rapid Point-of-Care Testing Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. Market Size & Growth Trajectory, 2021–2035 (US$ Billion)
2.8. Key Revenue Pools and High-Growth Opportunity Areas
2.9. Fastest-Growing Technology and Application Segments
2.10. Regional Growth Hotspots
2.11. Competitive Intensity Snapshot

What this section provides: This section gives decision-makers a concise assessment of U.S. market size, historical performance, 2025 positioning, forecast growth, high-potential testing categories, technology shifts, regional opportunities, and competitive intensity through 2035.

3. U.S. Rapid Point-of-Care Testing Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Expansion of Decentralized and Near-Patient Diagnostic Testing
3.1.2. High U.S. Burden of Respiratory and Infectious Diseases
3.1.3. Increasing Diabetes and Cardiometabolic Disease Prevalence
3.1.4. Growth of Urgent-Care, Retail Clinic and Physician-Office Testing
3.1.5. Expansion of CLIA-Waived Diagnostic Testing
3.1.6. Demand for Faster Clinical Decision-Making
3.1.7. Increasing Adoption of Rapid Molecular Diagnostics
3.1.8. Growing Consumer Acceptance of Home and Self-Testing
3.1.9. Antimicrobial Stewardship and Same-Visit Treatment Requirements

3.2. Restraints and Their Impact Analysis
3.2.1. Higher Per-Test Cost of Molecular POC Diagnostics
3.2.2. Variable Reimbursement Across Point-of-Care Applications
3.2.3. Sensitivity Limitations of Selected Rapid Antigen Technologies
3.2.4. Quality-Control and Operator-Competency Requirements
3.2.5. Central Laboratory Competition for High-Volume Testing
3.2.6. Seasonal Volatility in Respiratory Testing Demand
3.2.7. Instrument and Assay Menu Fragmentation

3.3. Opportunities and Their Impact Analysis
3.3.1. Ultra-Rapid Molecular PCR and NAAT Platforms
3.3.2. Multiplex Respiratory and Syndromic Testing
3.3.3. Point-of-Care STI and Sexual-Health Diagnostics
3.3.4. Decentralized HbA1c and Cardiometabolic Testing
3.3.5. Pharmacy-Based Clinical Testing
3.3.6. Home Diagnostic Testing Integrated with Telehealth
3.3.7. Rural and Medically Underserved Community Testing
3.3.8. Multi-Assay Platform Expansion and Menu Consolidation

3.4. Challenges and Their Impact Analysis
3.4.1. Balancing Diagnostic Accuracy with Speed and Cost
3.4.2. Maintaining Supply Reliability During Seasonal Demand Surges
3.4.3. EHR, LIS and Middleware Connectivity Complexity
3.4.4. Managing Large Distributed Analyzer Fleets
3.4.5. Regulatory Complexity Across Professional and OTC Testing
3.4.6. Test Utilization Governance and Clinical Appropriateness

3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Workflow Economics Analysis
3.6.1. Time-to-Result Versus Time-to-Clinical-Action
3.6.2. Central Laboratory Versus POC Testing Economics
3.6.3. Patient Throughput and Repeat-Visit Reduction
3.6.4. Impact on Emergency Department and Urgent-Care Workflow
3.6.5. Impact on Antimicrobial Stewardship and Treatment Decisions

3.7. Hospital and Health System Procurement Behavior Analysis
3.7.1. Instrument Standardization
3.7.2. Reagent Rental and Placement Models
3.7.3. Total Cost per Reportable Result
3.7.4. Analyzer Connectivity and Cybersecurity Requirements
3.7.5. Vendor Consolidation and Enterprise Contracting

What this section provides: This section explains the epidemiological, economic, clinical, regulatory, technology, and workflow factors driving U.S. rapid POC testing demand while identifying adoption barriers, emerging opportunities, and procurement considerations that can influence market growth.

4. U.S. Rapid Point-of-Care Testing Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal

4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry

4.3. Pricing Trend Analysis by Region, 2025–2035
4.3.1. Instrument Pricing Trends
4.3.2. Cartridge and Consumable Pricing Trends
4.3.3. Rapid Antigen Test Pricing Trends
4.3.4. Rapid Molecular Test Pricing Trends
4.3.5. Reagent Rental and Placement Economics

4.4. Value Chain & Supply Chain Analysis
4.4.1. Diagnostic Raw Materials and Reagents
4.4.2. Biosensors, Antibodies and Molecular Reagents
4.4.3. Cartridge and Microfluidic Components
4.4.4. Analyzer Manufacturing
4.4.5. Distribution and Logistics
4.4.6. End-User Deployment and Recurring Consumables

4.5. Impact of Digitalization and Connected Point-of-Care Diagnostics
4.5.1. LIS and EHR Connectivity
4.5.2. Point-of-Care Middleware
4.5.3. Remote Analyzer Fleet Management
4.5.4. Digital Result Reporting and Patient Connectivity

4.6. Application & Innovation Landscape
4.7. FDA Regulatory Framework Analysis
4.7.1. 510(k) Premarket Notification Pathway
4.7.2. De Novo Classification Pathway
4.7.3. Premarket Approval Considerations
4.7.4. OTC and At-Home Testing Regulatory Pathways
4.7.5. Post-Market Surveillance and Quality Requirements

4.8. CLIA Regulatory & Waiver Landscape
4.8.1. CLIA-Waived Testing
4.8.2. Provider-Performed Microscopy and Moderate Complexity
4.8.3. Operator Training and Quality Control Requirements
4.8.4. Impact of CLIA Waiver on Commercial Addressable Market

4.9. CMS Reimbursement and Coverage Landscape
4.9.1. Clinical Laboratory Fee Schedule Considerations
4.9.2. CPT Coding and POC Test Reimbursement
4.9.3. Medicare and Commercial Payer Dynamics
4.9.4. Reimbursement Economics Across Decentralized Settings

4.10. Import/Export Restrictions & Tariff Impact
4.11. Government Initiatives and Public Health Testing Programs
4.12. Respiratory Disease Preparedness and Stockpiling Dynamics
4.13. Impact of Escalating Geopolitical and Supply-Chain Tensions
4.14. Hospital Value Analysis Committee Decision Framework
4.15. Point-of-Care Device Connectivity, Data Security & Cybersecurity Analysis

What this section provides: This section evaluates the external commercial environment surrounding rapid POC diagnostics, including regulation, CLIA requirements, reimbursement, test pricing, supply chains, connectivity, competitive forces, public-health programs, and institutional purchasing requirements.

5. U.S. Rapid Point-of-Care Testing Devices Market – By Product Category

5.1. Overview
5.1.1. Segment Share Analysis, By Product Category, 2025 & 2035 (%)
5.1.2. Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)

5.1.3. Rapid Infectious Disease Testing Devices
5.1.3.1. Influenza Rapid Testing Devices
5.1.3.2. COVID-19 Rapid Testing Devices
5.1.3.3. RSV Rapid Testing Devices
5.1.3.4. Combination Influenza/COVID-19 Testing Devices
5.1.3.5. Multiplex Influenza/COVID-19/RSV Testing Devices
5.1.3.6. Group A Streptococcus Testing Devices
5.1.3.7. HIV Rapid Testing Devices
5.1.3.8. Hepatitis Rapid Testing Devices
5.1.3.9. STI Rapid Testing Devices
5.1.3.10. Other Infectious Disease Rapid Testing Devices

5.1.4. Blood Glucose and Diabetes POC Testing Devices
5.1.4.1. Blood Glucose Testing Systems
5.1.4.2. HbA1c POC Testing Devices
5.1.4.3. Ketone Testing Devices
5.1.4.4. Combined Metabolic Testing Systems

5.1.5. Cardiometabolic and Cardiac Marker POC Testing Devices
5.1.5.1. Troponin Testing Devices
5.1.5.2. BNP and NT-proBNP Testing Devices
5.1.5.3. Lipid Testing Systems
5.1.5.4. Other Cardiac Marker Testing Devices

5.1.6. Coagulation and Hemostasis POC Testing Devices
5.1.6.1. PT/INR Testing Devices
5.1.6.2. Activated Clotting Time Testing Devices
5.1.6.3. Other Coagulation Testing Devices

5.1.7. Pregnancy, Fertility and Women’s Health Rapid Testing Devices
5.1.7.1. Pregnancy Testing Devices
5.1.7.2. Ovulation and Fertility Testing Devices
5.1.7.3. Vaginal Infection Rapid Diagnostics
5.1.7.4. Other Women’s Health POC Tests

5.1.8. Other Rapid POC Testing Devices
5.1.8.1. Blood Gas and Electrolyte Testing Devices
5.1.8.2. Hematology POC Devices
5.1.8.3. Urinalysis POC Devices
5.1.8.4. Renal Function Testing Devices
5.1.8.5. Gastrointestinal and Fecal Testing Devices
5.1.8.6. Other Near-Patient Testing Devices

What this section provides: This section quantifies demand across major rapid POC device categories and identifies which product groups, assay menus, and recurring consumables are expected to generate the strongest revenue contribution and fastest growth through 2035.

6. U.S. Rapid Point-of-Care Testing Devices Market – By Application

6.1. Overview
6.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)
6.1.2. Market Size and Forecast, By Application, 2021–2035 (US$ Billion)

6.1.3. Respiratory Infection Diagnosis
6.1.3.1. Influenza Diagnosis
6.1.3.2. COVID-19 Diagnosis
6.1.3.3. RSV Diagnosis
6.1.3.4. Streptococcal Pharyngitis Diagnosis
6.1.3.5. Multiplex Respiratory Syndrome Diagnosis

6.1.4. Diabetes and Metabolic Disease Management
6.1.4.1. Routine Glucose Monitoring
6.1.4.2. HbA1c Monitoring
6.1.4.3. Ketone Assessment
6.1.4.4. Lipid and Cardiometabolic Assessment

6.1.5. Acute Cardiac and Critical-Care Decision Support
6.1.5.1. Acute Myocardial Injury Assessment
6.1.5.2. Heart Failure Assessment
6.1.5.3. Blood Gas and Electrolyte Assessment
6.1.5.4. Critical-Care Metabolic Assessment

6.1.6. Infectious Disease and Sexual-Health Screening
6.1.6.1. HIV Screening
6.1.6.2. Hepatitis Screening
6.1.6.3. Sexually Transmitted Infection Testing
6.1.6.4. Community Infectious Disease Screening

6.1.7. Pregnancy, Fertility and Women’s Health
6.1.7.1. Pregnancy Confirmation
6.1.7.2. Fertility and Ovulation Assessment
6.1.7.3. Vaginal Infection Diagnosis
6.1.7.4. Reproductive Health Screening

6.1.8. Coagulation and Anticoagulation Management
6.1.8.1. Warfarin Monitoring
6.1.8.2. Perioperative Coagulation Assessment
6.1.8.3. Cardiac and Interventional Procedure Monitoring
6.1.8.4. Patient Self-Testing and Home Anticoagulation Monitoring

6.1.9. Other Applications

What this section provides: This section identifies the clinical use cases creating rapid POC testing demand and helps clients prioritize applications where same-visit diagnosis, faster therapeutic decisions, reduced patient follow-up, and decentralized testing provide the strongest clinical and economic value.

7. U.S. Rapid Point-of-Care Testing Devices Market – By End User

7.1. Overview
7.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
7.1.2. Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

7.1.3. Hospitals and Integrated Health Systems
7.1.3.1. Emergency Departments
7.1.3.2. Inpatient and Critical-Care Units
7.1.3.3. Hospital Outpatient Departments
7.1.3.4. Operating Rooms and Procedural Areas

7.1.4. Physician Offices and Primary-Care Clinics
7.1.4.1. Family Medicine Practices
7.1.4.2. Pediatric Practices
7.1.4.3. Internal Medicine Practices
7.1.4.4. Endocrinology and Specialty Practices

7.1.5. Urgent-Care Centers and Retail Clinics
7.1.5.1. Independent Urgent-Care Centers
7.1.5.2. Multi-Site Urgent-Care Networks
7.1.5.3. Retail Health Clinics
7.1.5.4. Employer and Occupational Health Clinics

7.1.6. Home Care and Self-Testing
7.1.6.1. OTC Rapid Diagnostic Testing
7.1.6.2. Prescription Home Testing
7.1.6.3. Home Chronic-Disease Monitoring
7.1.6.4. Digitally Connected and Telehealth-Linked Testing

7.1.7. Community Health Centers, Pharmacies and Other Decentralized Sites
7.1.7.1. Federally Qualified Health Centers
7.1.7.2. Retail and Community Pharmacies
7.1.7.3. Public Health Clinics
7.1.7.4. Nursing and Long-Term Care Facilities
7.1.7.5. Mobile Health Units
7.1.7.6. Correctional and Institutional Healthcare Settings
7.1.7.7. School and University Health Programs

What this section provides: This section determines which care settings and buyer groups are expected to generate the highest testing volumes, analyzer placements, recurring cartridge demand, and commercial opportunities across professional and consumer point-of-care testing.

8. U.S. Rapid Point-of-Care Testing Devices Market – By Technology Type

8.1. Overview
8.1.1. Segment Share Analysis, By Technology Type, 2025 & 2035 (%)
8.1.2. Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)

8.1.3. Lateral Flow Immunoassay
8.1.3.1. Visual Lateral Flow Assays
8.1.3.2. Reader-Assisted Lateral Flow Assays
8.1.3.3. Multiplex Lateral Flow Assays

8.1.4. Molecular PCR and Nucleic Acid Amplification Technologies
8.1.4.1. Rapid PCR
8.1.4.2. Isothermal Nucleic Acid Amplification
8.1.4.3. Cartridge-Based Molecular Diagnostics
8.1.4.4. Multiplex Molecular POC Platforms

8.1.5. Electrochemical and Biosensor-Based Technologies
8.1.5.1. Electrochemical Glucose Biosensors
8.1.5.2. Enzyme-Based Biosensors
8.1.5.3. Multi-Analyte Electrochemical Systems

8.1.6. Fluorescence and Digital Immunoassay Technologies
8.1.6.1. Fluorescence Immunoassay Readers
8.1.6.2. Digital Immunoassay Systems
8.1.6.3. Quantitative and Semi-Quantitative Immunoassays

8.1.7. Microfluidic and Cartridge-Based Integrated Systems
8.1.7.1. Lab-on-Chip Platforms
8.1.7.2. Integrated Sample-to-Answer Cartridges
8.1.7.3. Multi-Analyte Microfluidic Platforms
8.1.7.4. Disposable Cartridge-Based Testing Systems

What this section provides: This section evaluates the diagnostic technologies shaping the market and identifies how rapid PCR, lateral flow, digital immunoassays, biosensors, microfluidics, and integrated cartridge platforms will alter test economics and competitive positioning through 2035.

9. U.S. Rapid Point-of-Care Testing Devices Market – By Geography

9.1. Introduction

9.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
9.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
9.1.3. Regional POC Test Utilization and Healthcare Infrastructure Analysis
9.1.4. CLIA-Waived Testing Site Penetration Analysis
9.1.5. Regional Respiratory and Chronic Disease Demand Analysis
9.1.6. Regional Reimbursement and Procurement Dynamics
9.1.7. Urgent-Care, Physician-Office and Retail Testing Density Analysis

9.2. West Region

9.2.1. Regional Overview & Trends
9.2.2. West Region Rapid POC Testing Key Manufacturers, Distributors & Procurement Ecosystem
9.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.2.4. West Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.5. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.6. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.7. West Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)

9.2.8. California

9.2.8.1. Overview
9.2.8.2. California Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.8.3. California Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.8.4. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.8.5. California Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.2.8.6. California POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.2.9. Washington

9.2.9.1. Overview
9.2.9.2. Washington Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.9.3. Washington Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.9.4. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.9.5. Washington Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.2.9.6. Washington POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.2.10. Arizona

9.2.10.1. Overview
9.2.10.2. Arizona Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.10.3. Arizona Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.10.4. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.10.5. Arizona Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.2.10.6. Arizona POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.2.11. Colorado

9.2.11.1. Overview
9.2.11.2. Colorado Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.11.3. Colorado Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.11.4. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.11.5. Colorado Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.2.11.6. Colorado POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.2.12. Oregon

9.2.12.1. Overview
9.2.12.2. Oregon Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.12.3. Oregon Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.12.4. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.12.5. Oregon Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.2.12.6. Oregon POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.2.13. Utah

9.2.13.1. Overview
9.2.13.2. Utah Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.13.3. Utah Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.13.4. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.13.5. Utah Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.2.13.6. Utah POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.2.14. Nevada

9.2.14.1. Overview
9.2.14.2. Nevada Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.14.3. Nevada Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.14.4. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.14.5. Nevada Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.2.14.6. Nevada POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.2.15. New Mexico

9.2.15.1. Overview
9.2.15.2. New Mexico Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.15.3. New Mexico Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.15.4. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.15.5. New Mexico Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.2.15.6. New Mexico POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.2.16. Idaho

9.2.16.1. Overview
9.2.16.2. Idaho Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.16.3. Idaho Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.16.4. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.16.5. Idaho Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.2.16.6. Idaho POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.2.17. Montana

9.2.17.1. Overview
9.2.17.2. Montana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.17.3. Montana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.17.4. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.17.5. Montana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.2.17.6. Montana POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.2.18. Wyoming

9.2.18.1. Overview
9.2.18.2. Wyoming Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.18.3. Wyoming Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.18.4. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.18.5. Wyoming Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.2.18.6. Wyoming POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.2.19. Alaska

9.2.19.1. Overview
9.2.19.2. Alaska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.19.3. Alaska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.19.4. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.19.5. Alaska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.2.19.6. Alaska POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.2.20. Hawaii

9.2.20.1. Overview
9.2.20.2. Hawaii Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.20.3. Hawaii Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.20.4. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.20.5. Hawaii Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.2.20.6. Hawaii POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.3. Northeast Region

9.3.1. Regional Overview & Trends
9.3.2. Northeast Region Rapid POC Testing Key Manufacturers, Distributors & Procurement Ecosystem
9.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.3.4. Northeast Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.5. Northeast Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.6. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.7. Northeast Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)

9.3.8. New York

9.3.8.1. Overview
9.3.8.2. New York Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.8.3. New York Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.8.4. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.8.5. New York Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.3.8.6. New York POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.3.9. Massachusetts

9.3.9.1. Overview
9.3.9.2. Massachusetts Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.9.3. Massachusetts Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.9.4. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.9.5. Massachusetts Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.3.9.6. Massachusetts POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.3.10. New Jersey

9.3.10.1. Overview
9.3.10.2. New Jersey Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.10.3. New Jersey Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.10.4. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.10.5. New Jersey Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.3.10.6. New Jersey POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.3.11. Pennsylvania

9.3.11.1. Overview
9.3.11.2. Pennsylvania Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.11.3. Pennsylvania Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.11.4. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.11.5. Pennsylvania Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.3.11.6. Pennsylvania POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.3.12. Connecticut

9.3.12.1. Overview
9.3.12.2. Connecticut Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.12.3. Connecticut Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.12.4. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.12.5. Connecticut Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.3.12.6. Connecticut POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.3.13. Maine

9.3.13.1. Overview
9.3.13.2. Maine Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.13.3. Maine Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.13.4. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.13.5. Maine Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.3.13.6. Maine POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.3.14. Vermont

9.3.14.1. Overview
9.3.14.2. Vermont Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.14.3. Vermont Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.14.4. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.14.5. Vermont Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.3.14.6. Vermont POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.3.15. New Hampshire

9.3.15.1. Overview
9.3.15.2. New Hampshire Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.15.3. New Hampshire Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.15.4. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.15.5. New Hampshire Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.3.15.6. New Hampshire POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.3.16. Rhode Island

9.3.16.1. Overview
9.3.16.2. Rhode Island Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.16.3. Rhode Island Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.16.4. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.16.5. Rhode Island Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.3.16.6. Rhode Island POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.3.17. Delaware

9.3.17.1. Overview
9.3.17.2. Delaware Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.17.3. Delaware Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.17.4. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.17.5. Delaware Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.3.17.6. Delaware POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.4. South Region

9.4.1. Regional Overview & Trends
9.4.2. South Region Rapid POC Testing Key Manufacturers, Distributors & Procurement Ecosystem
9.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.4.4. South Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.5. South Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.6. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.7. South Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)

9.4.8. Texas

9.4.8.1. Overview
9.4.8.2. Texas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.8.3. Texas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.8.4. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.8.5. Texas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.8.6. Texas POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.4.9. Florida

9.4.9.1. Overview
9.4.9.2. Florida Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.9.3. Florida Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.9.4. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.9.5. Florida Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.9.6. Florida POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.4.10. Georgia

9.4.10.1. Overview
9.4.10.2. Georgia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.10.3. Georgia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.10.4. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.10.5. Georgia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.10.6. Georgia POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.4.11. North Carolina

9.4.11.1. Overview
9.4.11.2. North Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.11.3. North Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.11.4. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.11.5. North Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.11.6. North Carolina POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.4.12. Tennessee

9.4.12.1. Overview
9.4.12.2. Tennessee Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.12.3. Tennessee Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.12.4. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.12.5. Tennessee Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.12.6. Tennessee POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.4.13. South Carolina

9.4.13.1. Overview
9.4.13.2. South Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.13.3. South Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.13.4. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.13.5. South Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.13.6. South Carolina POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.4.14. Alabama

9.4.14.1. Overview
9.4.14.2. Alabama Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.14.3. Alabama Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.14.4. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.14.5. Alabama Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.14.6. Alabama POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.4.15. Mississippi

9.4.15.1. Overview
9.4.15.2. Mississippi Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.15.3. Mississippi Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.15.4. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.15.5. Mississippi Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.15.6. Mississippi POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.4.16. Louisiana

9.4.16.1. Overview
9.4.16.2. Louisiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.16.3. Louisiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.16.4. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.16.5. Louisiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.16.6. Louisiana POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.4.17. Arkansas

9.4.17.1. Overview
9.4.17.2. Arkansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.17.3. Arkansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.17.4. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.17.5. Arkansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.17.6. Arkansas POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.4.18. Kentucky

9.4.18.1. Overview
9.4.18.2. Kentucky Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.18.3. Kentucky Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.18.4. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.18.5. Kentucky Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.18.6. Kentucky POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.4.19. Oklahoma

9.4.19.1. Overview
9.4.19.2. Oklahoma Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.19.3. Oklahoma Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.19.4. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.19.5. Oklahoma Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.19.6. Oklahoma POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.4.20. Virginia

9.4.20.1. Overview
9.4.20.2. Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.20.3. Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.20.4. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.20.5. Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.20.6. Virginia POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.4.21. Maryland

9.4.21.1. Overview
9.4.21.2. Maryland Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.21.3. Maryland Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.21.4. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.21.5. Maryland Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.21.6. Maryland POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.4.22. West Virginia

9.4.22.1. Overview
9.4.22.2. West Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.22.3. West Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.22.4. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.22.5. West Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.4.22.6. West Virginia POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.5. Midwest Region

9.5.1. Regional Overview & Trends
9.5.2. Midwest Region Rapid POC Testing Key Manufacturers, Distributors & Procurement Ecosystem
9.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.5.4. Midwest Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.5. Midwest Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.6. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.7. Midwest Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)

9.5.8. Illinois

9.5.8.1. Overview
9.5.8.2. Illinois Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.8.3. Illinois Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.8.4. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.8.5. Illinois Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.5.8.6. Illinois POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.5.9. Ohio

9.5.9.1. Overview
9.5.9.2. Ohio Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.9.3. Ohio Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.9.4. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.9.5. Ohio Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.5.9.6. Ohio POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.5.10. Michigan

9.5.10.1. Overview
9.5.10.2. Michigan Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.10.3. Michigan Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.10.4. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.10.5. Michigan Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.5.10.6. Michigan POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.5.11. Minnesota

9.5.11.1. Overview
9.5.11.2. Minnesota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.11.3. Minnesota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.11.4. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.11.5. Minnesota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.5.11.6. Minnesota POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.5.12. Indiana

9.5.12.1. Overview
9.5.12.2. Indiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.12.3. Indiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.12.4. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.12.5. Indiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.5.12.6. Indiana POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.5.13. Wisconsin

9.5.13.1. Overview
9.5.13.2. Wisconsin Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.13.3. Wisconsin Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.13.4. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.13.5. Wisconsin Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.5.13.6. Wisconsin POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.5.14. Missouri

9.5.14.1. Overview
9.5.14.2. Missouri Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.14.3. Missouri Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.14.4. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.14.5. Missouri Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.5.14.6. Missouri POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.5.15. Iowa

9.5.15.1. Overview
9.5.15.2. Iowa Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.15.3. Iowa Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.15.4. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.15.5. Iowa Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.5.15.6. Iowa POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.5.16. Kansas

9.5.16.1. Overview
9.5.16.2. Kansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.16.3. Kansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.16.4. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.16.5. Kansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.5.16.6. Kansas POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.5.17. Nebraska

9.5.17.1. Overview
9.5.17.2. Nebraska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.17.3. Nebraska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.17.4. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.17.5. Nebraska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.5.17.6. Nebraska POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.5.18. North Dakota

9.5.18.1. Overview
9.5.18.2. North Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.18.3. North Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.18.4. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.18.5. North Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.5.18.6. North Dakota POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

9.5.19. South Dakota

9.5.19.1. Overview
9.5.19.2. South Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.19.3. South Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.19.4. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.19.5. South Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.5.19.6. South Dakota POC Testing Infrastructure, CLIA-Waived Site Penetration & Procurement Dynamics

What this section provides: This section delivers detailed four-region and all-50-state market intelligence, enabling clients to identify high-value rapid-testing geographies, CLIA-waived testing concentration, hospital and urgent-care demand hubs, technology-adoption hotspots, rural diagnostic opportunities, and state-level commercialization priorities.

10. U.S. Rapid Point-of-Care Testing Devices Market: Competitive Landscape & Company Profiles

10.1. Market Share Analysis, 2025
10.2. Competitive Benchmarking
10.2.1. Product Portfolio Breadth
10.2.2. Installed Analyzer Base
10.2.3. Rapid Molecular Testing Capability
10.2.4. CLIA-Waived Assay Portfolio
10.2.5. OTC and Home Testing Presence
10.2.6. Connectivity and Digital Integration
10.2.7. Distribution and Health System Contracting Strength

10.3. Company Positioning Matrix
10.3.1. Leaders
10.3.2. Challengers
10.3.3. Innovators
10.3.4. Emerging Players

10.4. Company Profiles

10.4.1. Abbott Laboratories
10.4.2. Roche Diagnostics
10.4.3. QuidelOrtho Corporation
10.4.4. Becton, Dickinson and Company
10.4.5. Cepheid
10.4.6. bioMérieux
10.4.7. Siemens Healthineers
10.4.8. Werfen
10.4.9. Nova Biomedical
10.4.10. Radiometer Medical
10.4.11. DiaSorin
10.4.12. QIAGEN
10.4.13. OraSure Technologies
10.4.14. Trinity Biotech
10.4.15. SEKISUI Diagnostics
10.4.16. ACON Laboratories
10.4.17. Access Bio
10.4.18. iHealth Labs
10.4.19. Healgen Scientific
10.4.20. Wondfo
10.4.21. ARKRAY
10.4.22. EKF Diagnostics
10.4.23. PTS Diagnostics
10.4.24. Visby Medical
10.4.25. Baebies

10.5. Competitive Strategies
10.5.1. New Product Launches
10.5.2. FDA Clearances and CLIA Waivers
10.5.3. Acquisitions and Strategic Partnerships
10.5.4. Assay Menu Expansion
10.5.5. Hospital and IDN Contracting
10.5.6. Urgent-Care and Physician-Office Expansion
10.5.7. Retail and Consumer Diagnostic Distribution

Company Profile Coverage: Each company profile will include company overview, U.S. rapid POC testing portfolio, key analyzers and assays, technology positioning, U.S. market strategy, FDA and CLIA status, recent product launches, partnerships and acquisitions, competitive strengths, strategic priorities, and recent developments.

What this section provides: This section gives clients competitive benchmarking, market-share visibility, installed-base intelligence, assay-menu positioning, regulatory progress, technology differentiation, commercial strategy, and company-level insights across approximately 25 major rapid point-of-care testing participants.

11. U.S. Rapid Point-of-Care Testing Devices Market: Future Market Outlook, 2026–2035

11.1. Scenario Analysis
11.1.1. Optimistic Scenario
11.1.2. Realistic Scenario
11.1.3. Pessimistic Scenario

11.2. Disruptive Technologies Impact
11.2.1. Ultra-Rapid Molecular PCR and NAAT
11.2.2. Multiplex Respiratory and Syndromic Diagnostic Platforms
11.2.3. Microfluidic and Lab-on-Chip Diagnostics
11.2.4. Digitally Connected POC Testing and Middleware
11.2.5. AI-Assisted Test Interpretation and Clinical Decision Support
11.2.6. Home Molecular and Multi-Analyte Testing
11.2.7. Telehealth-Integrated Diagnostic Testing

11.3. Future of CLIA-Waived Molecular Testing
11.4. Transition from Single-Analyte to Multi-Assay Platforms
11.5. Evolution of Antigen Versus Molecular Testing Economics
11.6. Emerging Business Models
11.6.1. Reagent Rental Models
11.6.2. Analyzer Placement Models
11.6.3. Test-as-a-Service Models
11.6.4. Retail and Consumer Diagnostic Models

11.7. Business Opportunities for Startups and Existing Players
11.8. Investment Prioritization Matrix
11.9. High-Potential White-Space Opportunities
11.10. Long-Term Market Structure Through 2035

What this section provides: This section prepares clients for technological disruption, market-structure changes, assay-menu expansion, decentralization trends, investment opportunities, and potential adoption scenarios shaping the U.S. rapid POC testing market through 2035.

12. U.S. Rapid Point-of-Care Testing Devices Market: Strategic Recommendations

12.1. Recommendations for Rapid POC Device Manufacturers
12.1.1. Build Broader CLIA-Waived Assay Menus
12.1.2. Prioritize Sample-to-Answer Workflow Simplicity
12.1.3. Strengthen Analyzer Connectivity and Remote Management
12.1.4. Optimize Cartridge Economics and Manufacturing Scale
12.1.5. Develop Evidence Around Clinical Workflow Savings

12.2. Recommendations for Hospitals and Integrated Delivery Networks
12.2.1. Optimize Analyzer Fleet Standardization
12.2.2. Establish POC Test Utilization Governance
12.2.3. Integrate POC Results with LIS and EHR Infrastructure
12.2.4. Evaluate Total Cost per Clinical Decision
12.2.5. Align Rapid Testing with Antimicrobial Stewardship Programs

12.3. Recommendations for Physician Offices and Urgent-Care Providers
12.3.1. Prioritize High-Utilization Assay Menus
12.3.2. Evaluate Antigen Versus Molecular Testing Economics
12.3.3. Optimize Testing Workflow and Patient Throughput
12.3.4. Standardize Multi-Site Quality Management

12.4. Recommendations for Pharmacies, Retail Clinics and Consumer Testing Companies
12.5. Recommendations for Investors and Private Equity Firms
12.6. Recommendations for Diagnostic Distributors and Channel Partners
12.7. Recommendations for New Entrants and Startups
12.8. Go-to-Market Strategy Considerations
12.8.1. Hospital and IDN Market Entry
12.8.2. Urgent-Care Market Entry
12.8.3. Physician-Office Market Entry
12.8.4. Retail Pharmacy Market Entry
12.8.5. Home and Consumer Testing Market Entry

12.9. Product Positioning and Portfolio Expansion Guidance
12.10. Geographic Market Prioritization
12.11. Pricing and Reimbursement Strategy Considerations

What this section provides: This section converts market intelligence into actionable recommendations for product development, clinical positioning, assay-menu strategy, channel expansion, hospital contracting, geographic prioritization, pricing, investment decisions, and competitive differentiation.

13. U.S. Rapid Point-of-Care Testing Devices Market: Disclaimer

13.1. Scope Limitation
13.2. Market Definition Limitation
13.3. Data Use Limitation
13.4. Market Sizing and Forecasting Limitation
13.5. Regulatory and Reimbursement Data Limitation
13.6. Company and Competitive Intelligence Limitation
13.7. Legal Disclaimer
13.8. Third-Party Data Disclaimer

What this section provides: This section clarifies the report’s market boundaries, analytical limitations, data-use conditions, forecasting assumptions, regulatory and reimbursement caveats, company-information limitations, and legal terms.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Rapid Point-of-Care Testing Devices Market: Market Definition and Scope
TABLE 3: U.S. Rapid Point-of-Care Testing Devices Market: Research Methodology Framework
TABLE 4: U.S. Rapid Point-of-Care Testing Devices Market: Key Assumptions
TABLE 5: U.S. Rapid Point-of-Care Testing Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Rapid Point-of-Care Testing Devices Market: Stakeholder Analysis
TABLE 7: U.S. Rapid Point-of-Care Testing Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Rapid Point-of-Care Testing Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Rapid Point-of-Care Testing Devices Market: Market Attractiveness Index
TABLE 10: U.S. Rapid Point-of-Care Testing Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Rapid Point-of-Care Testing Devices Market: Base Year Market Positioning, 2025
TABLE 12: U.S. Rapid Point-of-Care Testing Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 13: U.S. Rapid Point-of-Care Testing Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 14: U.S. Rapid Point-of-Care Testing Devices Market: High-Growth Opportunity Areas
TABLE 15: U.S. Rapid Point-of-Care Testing Devices Market: Drivers; Impact Analysis
TABLE 16: U.S. Rapid Point-of-Care Testing Devices Market: Restraints; Impact Analysis
TABLE 17: U.S. Rapid Point-of-Care Testing Devices Market: Opportunities; Impact Analysis
TABLE 18: U.S. Rapid Point-of-Care Testing Devices Market: Challenges; Impact Analysis
TABLE 19: U.S. Rapid Point-of-Care Testing Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 20: U.S. Rapid Point-of-Care Testing Devices Market: Clinical Workflow Economics Matrix
TABLE 21: U.S. Rapid Point-of-Care Testing Devices Market: Hospital and Health System Procurement Behavior Matrix
TABLE 22: U.S. Rapid Point-of-Care Testing Devices Market: PESTEL Analysis
TABLE 23: U.S. Rapid Point-of-Care Testing Devices Market: Porter’s Five Forces Analysis
TABLE 24: U.S. Rapid Point-of-Care Testing Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 25: U.S. Rapid Point-of-Care Testing Devices Market: Value Chain Analysis
TABLE 26: U.S. Rapid Point-of-Care Testing Devices Market: Supply Chain Analysis
TABLE 27: U.S. Rapid Point-of-Care Testing Devices Market: Digitalization and Connected POC Diagnostics Impact
TABLE 28: U.S. Rapid Point-of-Care Testing Devices Market: Application & Innovation Landscape
TABLE 29: U.S. Rapid Point-of-Care Testing Devices Market: FDA Regulatory Framework Analysis
TABLE 30: U.S. Rapid Point-of-Care Testing Devices Market: CLIA Regulatory & Waiver Landscape
TABLE 31: U.S. Rapid Point-of-Care Testing Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 32: U.S. Rapid Point-of-Care Testing Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 33: U.S. Rapid Point-of-Care Testing Devices Market: Government Initiatives and Public Health Testing Programs
TABLE 34: U.S. Rapid Point-of-Care Testing Devices Market: Respiratory Disease Preparedness and Stockpiling Dynamics
TABLE 35: U.S. Rapid Point-of-Care Testing Devices Market: Impact of Escalating Geopolitical Tensions
TABLE 36: U.S. Rapid Point-of-Care Testing Devices Market: Hospital Value Analysis Committee Decision Framework
TABLE 37: U.S. Rapid Point-of-Care Testing Devices Market: Connectivity, Data Security & Cybersecurity Analysis
TABLE 38: U.S. Rapid Point-of-Care Testing Devices Market: Product Category Snapshot, 2025
TABLE 39: Segment Dashboard; Definition and Scope, by Product Category
TABLE 40: U.S. Rapid Point-of-Care Testing Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 41: U.S. Rapid Point-of-Care Testing Devices Market: Segment Share Analysis, by Product Category, 2025 & 2035 (%)
TABLE 42: U.S. Rapid Point-of-Care Testing Devices Market: Rapid Infectious Disease Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 43: U.S. Rapid Point-of-Care Testing Devices Market: Blood Glucose and Diabetes POC Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 44: U.S. Rapid Point-of-Care Testing Devices Market: Cardiometabolic and Cardiac Marker POC Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 45: U.S. Rapid Point-of-Care Testing Devices Market: Coagulation and Hemostasis POC Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: U.S. Rapid Point-of-Care Testing Devices Market: Pregnancy, Fertility and Women’s Health Rapid Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: U.S. Rapid Point-of-Care Testing Devices Market: Other Rapid POC Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 48: U.S. Rapid Point-of-Care Testing Devices Market: Application Snapshot, 2025
TABLE 49: Segment Dashboard; Definition and Scope, by Application
TABLE 50: U.S. Rapid Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 51: U.S. Rapid Point-of-Care Testing Devices Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 52: U.S. Rapid Point-of-Care Testing Devices Market: Respiratory Infection Diagnosis Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 53: U.S. Rapid Point-of-Care Testing Devices Market: Diabetes and Metabolic Disease Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: U.S. Rapid Point-of-Care Testing Devices Market: Acute Cardiac and Critical-Care Decision Support Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: U.S. Rapid Point-of-Care Testing Devices Market: Infectious Disease and Sexual-Health Screening Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 56: U.S. Rapid Point-of-Care Testing Devices Market: Pregnancy, Fertility and Women’s Health Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: U.S. Rapid Point-of-Care Testing Devices Market: Coagulation and Anticoagulation Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 58: U.S. Rapid Point-of-Care Testing Devices Market: Other Applications Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 59: U.S. Rapid Point-of-Care Testing Devices Market: End User Snapshot, 2025
TABLE 60: Segment Dashboard; Definition and Scope, by End User
TABLE 61: U.S. Rapid Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 62: U.S. Rapid Point-of-Care Testing Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 63: U.S. Rapid Point-of-Care Testing Devices Market: Hospitals and Integrated Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: U.S. Rapid Point-of-Care Testing Devices Market: Physician Offices and Primary-Care Clinics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 65: U.S. Rapid Point-of-Care Testing Devices Market: Urgent-Care Centers and Retail Clinics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: U.S. Rapid Point-of-Care Testing Devices Market: Home Care and Self-Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 67: U.S. Rapid Point-of-Care Testing Devices Market: Community Health Centers, Pharmacies and Other Decentralized Sites Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 68: U.S. Rapid Point-of-Care Testing Devices Market: Technology Type Snapshot, 2025
TABLE 69: Segment Dashboard; Definition and Scope, by Technology Type
TABLE 70: U.S. Rapid Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 71: U.S. Rapid Point-of-Care Testing Devices Market: Segment Share Analysis, by Technology Type, 2025 & 2035 (%)
TABLE 72: U.S. Rapid Point-of-Care Testing Devices Market: Lateral Flow Immunoassay Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: U.S. Rapid Point-of-Care Testing Devices Market: Molecular PCR and Nucleic Acid Amplification Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 74: U.S. Rapid Point-of-Care Testing Devices Market: Electrochemical and Biosensor-Based Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: U.S. Rapid Point-of-Care Testing Devices Market: Fluorescence and Digital Immunoassay Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 76: U.S. Rapid Point-of-Care Testing Devices Market: Microfluidic and Cartridge-Based Integrated Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 77: U.S. Rapid Point-of-Care Testing Devices Market: Regional Snapshot, 2025
TABLE 78: Segment Dashboard; Definition and Scope, by Geography
TABLE 79: U.S. Rapid Point-of-Care Testing Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 80: U.S. Rapid Point-of-Care Testing Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 81: West Region U.S. Rapid Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 82: West Region U.S. Rapid Point-of-Care Testing Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 83: West Region U.S. Rapid Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 84: California Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 85: Washington Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 86: Arizona Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 87: Colorado Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 88: Oregon Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 89: Utah Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 90: Nevada Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 91: New Mexico Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 92: Idaho Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 93: Montana Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 94: Wyoming Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 95: Alaska Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 96: Hawaii Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 97: Northeast Region U.S. Rapid Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 98: Northeast Region U.S. Rapid Point-of-Care Testing Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 99: Northeast Region U.S. Rapid Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 100: New York Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 101: Massachusetts Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 102: New Jersey Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 103: Pennsylvania Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 104: Connecticut Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 105: Maine Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 106: Vermont Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 107: New Hampshire Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 108: Rhode Island Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 109: Delaware Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 110: South Region U.S. Rapid Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 111: South Region U.S. Rapid Point-of-Care Testing Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 112: South Region U.S. Rapid Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 113: Texas Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 114: Florida Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 115: Georgia Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 116: North Carolina Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 117: Tennessee Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 118: South Carolina Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 119: Alabama Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 120: Mississippi Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 121: Louisiana Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 122: Arkansas Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 123: Kentucky Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 124: Oklahoma Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 125: Virginia Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 126: Maryland Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 127: West Virginia Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 128: Midwest Region U.S. Rapid Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 129: Midwest Region U.S. Rapid Point-of-Care Testing Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 130: Midwest Region U.S. Rapid Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 131: Illinois Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 132: Ohio Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 133: Michigan Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 134: Minnesota Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 135: Indiana Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 136: Wisconsin Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 137: Missouri Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 138: Iowa Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 139: Kansas Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 140: Nebraska Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 141: North Dakota Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 142: South Dakota Rapid Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 143: U.S. Rapid Point-of-Care Testing Devices Market: Competitive Landscape Snapshot, 2025
TABLE 144: U.S. Rapid Point-of-Care Testing Devices Market: Key Company Market Share Analysis, 2025
TABLE 145: U.S. Rapid Point-of-Care Testing Devices Market: Company Positioning Matrix
TABLE 146: U.S. Rapid Point-of-Care Testing Devices Market: Product Portfolio Benchmarking of Key Players
TABLE 147: U.S. Rapid Point-of-Care Testing Devices Market: Installed Base, CLIA-Waived Menu and Connectivity Benchmarking
TABLE 148: U.S. Rapid Point-of-Care Testing Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 149: Abbott Laboratories: Company Profile
TABLE 150: Roche Diagnostics: Company Profile
TABLE 151: QuidelOrtho Corporation: Company Profile
TABLE 152: Becton, Dickinson and Company: Company Profile
TABLE 153: Cepheid: Company Profile
TABLE 154: bioMérieux: Company Profile
TABLE 155: Siemens Healthineers: Company Profile
TABLE 156: Werfen: Company Profile
TABLE 157: Nova Biomedical: Company Profile
TABLE 158: Radiometer Medical: Company Profile
TABLE 159: DiaSorin: Company Profile
TABLE 160: QIAGEN: Company Profile
TABLE 161: OraSure Technologies: Company Profile
TABLE 162: Trinity Biotech: Company Profile
TABLE 163: SEKISUI Diagnostics: Company Profile
TABLE 164: ACON Laboratories: Company Profile
TABLE 165: Access Bio: Company Profile
TABLE 166: iHealth Labs: Company Profile
TABLE 167: Healgen Scientific: Company Profile
TABLE 168: Wondfo: Company Profile
TABLE 169: ARKRAY: Company Profile
TABLE 170: EKF Diagnostics: Company Profile
TABLE 171: PTS Diagnostics: Company Profile
TABLE 172: Visby Medical: Company Profile
TABLE 173: Baebies: Company Profile
TABLE 174: U.S. Rapid Point-of-Care Testing Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 175: U.S. Rapid Point-of-Care Testing Devices Market: Disruptive Technologies Impact Matrix
TABLE 176: U.S. Rapid Point-of-Care Testing Devices Market: Ultra-Rapid Molecular Testing Opportunity Analysis
TABLE 177: U.S. Rapid Point-of-Care Testing Devices Market: Multiplex and Syndromic Testing Growth Roadmap
TABLE 178: U.S. Rapid Point-of-Care Testing Devices Market: CLIA-Waived Molecular Testing Outlook
TABLE 179: U.S. Rapid Point-of-Care Testing Devices Market: Emerging Business Trends
TABLE 180: U.S. Rapid Point-of-Care Testing Devices Market: Investment Prioritization Matrix
TABLE 181: U.S. Rapid Point-of-Care Testing Devices Market: High-Potential White-Space Opportunities
TABLE 182: U.S. Rapid Point-of-Care Testing Devices Market: Strategic Recommendations for Device Manufacturers
TABLE 183: U.S. Rapid Point-of-Care Testing Devices Market: Strategic Recommendations for Hospitals and Health Systems
TABLE 184: U.S. Rapid Point-of-Care Testing Devices Market: Strategic Recommendations for Physician Offices and Urgent-Care Providers
TABLE 185: U.S. Rapid Point-of-Care Testing Devices Market: Strategic Recommendations for Pharmacies, Retail Clinics and Consumer Testing Companies
TABLE 186: U.S. Rapid Point-of-Care Testing Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 187: U.S. Rapid Point-of-Care Testing Devices Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 188: U.S. Rapid Point-of-Care Testing Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 189: U.S. Rapid Point-of-Care Testing Devices Market: Go-to-Market Strategy Considerations
TABLE 190: U.S. Rapid Point-of-Care Testing Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 191: U.S. Rapid Point-of-Care Testing Devices Market: Geographic Market Prioritization
TABLE 192: U.S. Rapid Point-of-Care Testing Devices Market: Pricing and Reimbursement Strategy Considerations
TABLE 193: U.S. Rapid Point-of-Care Testing Devices Market: Scope Limitation
TABLE 194: U.S. Rapid Point-of-Care Testing Devices Market: Market Definition Limitation
TABLE 195: U.S. Rapid Point-of-Care Testing Devices Market: Data Use Limitation
TABLE 196: U.S. Rapid Point-of-Care Testing Devices Market: Market Sizing and Forecasting Limitation
TABLE 197: U.S. Rapid Point-of-Care Testing Devices Market: Regulatory and Reimbursement Data Limitation
TABLE 198: U.S. Rapid Point-of-Care Testing Devices Market: Company and Competitive Intelligence Limitation
TABLE 199: U.S. Rapid Point-of-Care Testing Devices Market: Legal Disclaimer
TABLE 200: U.S. Rapid Point-of-Care Testing Devices Market: Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. Rapid Point-of-Care Testing Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Market Ecosystem
FIGURE 4: Stakeholder Landscape
FIGURE 5: U.S. Rapid Point-of-Care Testing Devices Market Attractiveness Analysis
FIGURE 6: U.S. Rapid Point-of-Care Testing Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 7: U.S. Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 8: U.S. Rapid Point-of-Care Testing Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 9: U.S. Rapid Point-of-Care Testing Devices Market Dynamics
FIGURE 10: Drivers Impact Framework
FIGURE 11: Restraints Impact Framework
FIGURE 12: Opportunities Impact Framework
FIGURE 13: Challenges Impact Framework
FIGURE 14: Innovation & Patent Landscape, 2021–2025
FIGURE 15: Clinical Workflow Economics Framework
FIGURE 16: Hospital and Health System Procurement Decision Framework
FIGURE 17: PESTEL Analysis
FIGURE 18: Porter’s Five Forces Analysis
FIGURE 19: Value Chain Analysis
FIGURE 20: Supply Chain Analysis
FIGURE 21: Point-of-Care Digital Connectivity Framework
FIGURE 22: FDA and CLIA Regulatory Pathway Framework
FIGURE 23: CMS Reimbursement Landscape
FIGURE 24: Hospital Value Analysis Committee Decision Framework
FIGURE 25: POC Device Connectivity and Cybersecurity Framework
FIGURE 26: Product Category Segment Market Share Analysis, 2025 & 2035
FIGURE 27: Product Category Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Rapid Infectious Disease Testing Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Blood Glucose and Diabetes POC Testing Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: Cardiometabolic and Cardiac Marker POC Testing Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: Coagulation and Hemostasis POC Testing Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 32: Pregnancy, Fertility and Women’s Health Rapid Testing Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: Other Rapid POC Testing Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 35: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Respiratory Infection Diagnosis Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: Diabetes and Metabolic Disease Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: Acute Cardiac and Critical-Care Decision Support Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 39: Infectious Disease and Sexual-Health Screening Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: Pregnancy, Fertility and Women’s Health Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Coagulation and Anticoagulation Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: Other Applications Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 44: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: Hospitals and Integrated Health Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 46: Physician Offices and Primary-Care Clinics Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 47: Urgent-Care Centers and Retail Clinics Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 48: Home Care and Self-Testing Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 49: Community Health Centers, Pharmacies and Other Decentralized Sites Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: Technology Type Segment Market Share Analysis, 2025 & 2035
FIGURE 51: Technology Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 52: Lateral Flow Immunoassay Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 53: Molecular PCR and Nucleic Acid Amplification Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 54: Electrochemical and Biosensor-Based Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 55: Fluorescence and Digital Immunoassay Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 56: Microfluidic and Cartridge-Based Integrated Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 57: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 58: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 59: West Region U.S. Rapid Point-of-Care Testing Devices Market Share and Leading Players, 2025
FIGURE 60: West Region Market Share Analysis by State, 2025
FIGURE 61: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: California Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: Washington Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 64: Arizona Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: Colorado Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: Oregon Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: Utah Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: Nevada Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: New Mexico Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: Idaho Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: Montana Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: Wyoming Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: Alaska Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: Hawaii Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: Northeast Region U.S. Rapid Point-of-Care Testing Devices Market Share and Leading Players, 2025
FIGURE 76: Northeast Region Market Share Analysis by State, 2025
FIGURE 77: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: New York Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: Massachusetts Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: New Jersey Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: Pennsylvania Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: Connecticut Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: Maine Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: Vermont Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: New Hampshire Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: Rhode Island Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: Delaware Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: South Region U.S. Rapid Point-of-Care Testing Devices Market Share and Leading Players, 2025
FIGURE 89: South Region Market Share Analysis by State, 2025
FIGURE 90: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: Texas Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: Florida Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: Georgia Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: North Carolina Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: Tennessee Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: South Carolina Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Alabama Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: Mississippi Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Louisiana Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: Arkansas Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: Kentucky Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Oklahoma Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: Virginia Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Maryland Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: West Virginia Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: Midwest Region U.S. Rapid Point-of-Care Testing Devices Market Share and Leading Players, 2025
FIGURE 107: Midwest Region Market Share Analysis by State, 2025
FIGURE 108: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: Illinois Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Ohio Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 111: Michigan Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 112: Minnesota Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: Indiana Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 114: Wisconsin Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 115: Missouri Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 116: Iowa Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 117: Kansas Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 118: Nebraska Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 119: North Dakota Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 120: South Dakota Rapid Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 121: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 122: Company Positioning Matrix
FIGURE 123: Key Player Product Portfolio Benchmarking
FIGURE 124: Installed Base and CLIA-Waived Menu Benchmarking
FIGURE 125: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 126: Rapid POC Diagnostic Innovation Roadmap
FIGURE 127: Future Market Scenario Analysis, 2026–2035
FIGURE 128: Disruptive Technologies Impact Matrix
FIGURE 129: Ultra-Rapid Molecular Testing Adoption Roadmap
FIGURE 130: Multiplex and Syndromic Testing Opportunity Map
FIGURE 131: CLIA-Waived Molecular Testing Growth Roadmap
FIGURE 132: Emerging Business Trends Matrix
FIGURE 133: Investment Prioritization Matrix
FIGURE 134: Strategic Growth Roadmap for U.S. Rapid POC Testing Device Companies
FIGURE 135: Hospital and Health System Adoption Strategy Framework
FIGURE 136: Urgent-Care and Physician-Office Commercialization Framework
FIGURE 137: Retail and Home Testing Market Entry Framework
FIGURE 138: Go-to-Market Strategy Framework
FIGURE 139: Product Positioning and Portfolio Expansion Framework
FIGURE 140: Geographic Market Prioritization Framework
FIGURE 141: Report Scope and Disclaimer Framework